REDWOOD CITY, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS), today announced that YUSIMRY™ (adalimumab-aqvh) is now available for commercial sale in the United States at a ...
The pharmacy benefit manager SmithRx has announced that through a partnership with the Mark Cuban Cost Plus Drug Company, it will offer Yusimry, an adalimumab biosimilar, for less than 90% of the cost ...
Mark Cuban Cost Plus Drug Company and Coherus BioSciences are planning to offer customers Yusimry (adalimumab-aqvh), a biosimilar of AbbVie's Humira (adalimumab injection), in July 2023. The ...
DALLAS, Texas and REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Mark Cuban Cost Plus Drug Company, PBC (“Cost Plus Drugs” or “Mark Cuban Cost Plus Drug Company”) and Coherus BioSciences, Inc ...
REDWOOD CITY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS) (“Coherus”, Nasdaq: CHRS) and specialty pharmacy Superior Biologics, Inc. (“Superior Biologics”) today ...
Please provide your email address to receive an email when new articles are posted on . Coherus’ adalimumab biosimilar, Yusimry, will enter the U.S. market in July at an 85% discount from AbbVie’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results